Castle Ryan D, Marzolf James, Morris Miranda, Bushell William C
Whole Health Oncology Institute, Ewa Beach, HI, United States.
Chopra Foundation, New York, NY, United States.
Front Oncol. 2025 Apr 15;15:1490621. doi: 10.3389/fonc.2025.1490621. eCollection 2025.
Growing bodies of evidence suggest that cannabis may play a significant role in both oncological palliative care and as a direct anticarcinogenic agent, but classification as a Schedule I substance has complicated research into its therapeutic potential, leaving the state of research scattered and heterogeneous. This meta-analysis was conducted to determine the scientific consensus on medical cannabis' viability in cancer treatment.
The aim of this meta-analysis was to systematically assess the existing literature on medical cannabis, focusing on its therapeutic potential, safety profiles, and role in cancer treatment.
This study synthesized data from over 10,000 peer-reviewed research papers, encompassing 39,767 data points related to cannabis and various health outcomes. Using sentiment analysis, the study identified correlations between cannabis use and supported, not supported, and unclear sentiments across multiple categories, including cancer dynamics, health metrics, and cancer treatments. A sensitivity analysis was conducted to validate the reliability of the findings.
The meta-analysis revealed a significant consensus supporting the use of medical cannabis in the categories of health metrics, cancer treatments, and cancer dynamics. The aggregated correlation strength of cannabis across all cancer topics indicates that support for medical cannabis is 31.38× stronger than opposition to it. The analysis highlighted the anti-inflammatory potential of cannabis, its use in managing cancer-related symptoms such as pain, nausea, and appetite loss, and explored the consensus on its use as an anticarcinogenic agent.
The findings indicate a strong and growing consensus within the scientific community regarding the therapeutic benefits of cannabis, particularly in the context of cancer. The consistent correlation strengths for cannabis as both a palliative adjunct and a potential anticarcinogenic agent redefine the consensus around cannabis as a medical intervention.
The consistency of positive sentiments across a wide range of studies suggests that cannabis should be re-evaluated within the medical community as a treatment option. The findings have implications for public health research, clinical practice, and discussions surrounding the legal status of medical cannabis. These results suggest a need for further research to explore the full therapeutic potential of cannabis and address knowledge gaps.
越来越多的证据表明,大麻可能在肿瘤姑息治疗以及作为一种直接的抗癌剂方面发挥重要作用,但被归类为一类药物使对其治疗潜力的研究变得复杂,导致研究状况分散且参差不齐。进行这项荟萃分析是为了确定关于医用大麻在癌症治疗中可行性的科学共识。
这项荟萃分析的目的是系统评估关于医用大麻的现有文献,重点关注其治疗潜力、安全性概况以及在癌症治疗中的作用。
本研究综合了10000多篇同行评议研究论文的数据,涵盖了39767个与大麻及各种健康结果相关的数据点。通过情感分析,该研究确定了大麻使用与多个类别(包括癌症动态、健康指标和癌症治疗)中支持、不支持和不明确情感之间的相关性。进行了敏感性分析以验证研究结果的可靠性。
荟萃分析显示,在健康指标、癌症治疗和癌症动态等类别中,存在支持使用医用大麻的显著共识。大麻在所有癌症主题上的综合相关强度表明,对医用大麻的支持比对其反对强31.38倍。分析突出了大麻的抗炎潜力、其在管理癌症相关症状(如疼痛、恶心和食欲减退)方面的用途,并探讨了其作为抗癌剂使用的共识。
研究结果表明,科学界对大麻的治疗益处,尤其是在癌症背景下,存在强烈且不断增长的共识。大麻作为姑息治疗辅助药物和潜在抗癌剂的一致相关强度重新定义了围绕大麻作为一种医学干预措施的共识。
广泛研究中积极情感的一致性表明,医用大麻应在医学界作为一种治疗选择重新进行评估。这些发现对公共卫生研究、临床实践以及围绕医用大麻法律地位的讨论具有影响。这些结果表明需要进一步研究以探索大麻的全部治疗潜力并填补知识空白。